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ABSTRACT The efficacy of mesotherapy in the treatment of female pattern hair 
loss (FPHL) has not yet been evaluated. Aim of the study was to compare the ini-
tial efficacy and safety of mesotherapy containing nutritional supplements to 
topical minoxidil 5% solution in FPHL. 30 patients with FPHL were randomly clas-
sified into two equal groups: Group A applied minoxidil 5% lotion twice daily; 
Group B was injected with mesotherapy once weekly. For both groups ultrasound 
biomicroscopy (UBM) was performed before and at the end of the 12th week of 
treatment. After treatment, no significant difference was found between both 
groups with regard to either improvement of hair density and hair loss (P=0.27 
and 0.056, respectively), nor the degree of improvement of Ludwig’s classification 
as assessed by the investigator (P=0.210). A significant difference was observed 
between both groups (P=0.001) with the highest degree of satisfaction in the me-
sotherapy group. In group A, no significant difference was found in the number of 
hair follicles or the diameter of the largest hair follicle (P=0.244 and 0.925, respec-
tively). In group B, a significant difference was found in the number of hair follicles 
(P=0.001), with no significant difference in the diameter of the largest hair follicle 
(P=0.105). The mesotherapy group showed more improvement with regard to the 
increase in the number of the hair follicles after treatment (P=0.007). Limitation of 
the study is small sample size, and relatively short duration of treatment. 
Mesotherapy, containing nutritional supplements only, is an effective, more ac-
ceptable to patients, and more tolerable modality compared with topical minoxi-
dil in the treatment of FPHL.
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INTRODUCTION
Female pattern hair loss (FPHL) is the most com-
mon hair loss disorder in women (1). It has been de-
fined as non-scarring progressive miniaturization of 
the hair follicle, usually with a characteristic pattern 
of distribution that occurs in genetically predisposed 
women (2).
Female pattern hair loss has a strikingly over-
whelming psychological effect; thus, successful treat-
ments are necessary (3). The US Food and Drug Ad-
ministration (FDA) has only approved topical minoxi-
dil 2% (4) and 5% (5) for treating FPHL. However, low 
patient compliance and satisfaction rates, as well as 
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the plethora of topical and often important systemic 
adverse effects have lead to a search for new treat-
ment options (6).
Mesotherapy is a technique which involves mi-
croinjection of medications and/or vitamins into the 
middle layer of the skin (7). It has received a lot of 
publicity in the media and on the internet about its 
possible role in androgenetic alopecia. However, the 
subject is controversial in view of lack of documented 
evidence (8).
Ultrasound biomicroscopy (UBM) is a non-inva-
sive imaging technique used in the examination of 
several skin diseases (9), including hair and scalp dis-
eases (10). 
The aim of this study was to compare the initial effi-
cacy and safety of mesotherapy containing only nutri-
tional supplements to a minoxidil 5% lotion in FPHL.
METHODS
This randomized controlled trial included 30 pa-
tients with FPHL. Patients were recruited from the 
dermatology outpatient clinic of our university over 
the period from October 2013 to December 2014. Di-
agnosis of FPHL was based on thorough history and 
clinical examination to exclude similar conditions, 
especially telogen effluvium (11). The study included 
female patients who were not using topical, intra-
lesional, or systemic therapy for FPHL, hair perma-
nent, or dyes during and 6 months before the study. 
Patients on medications as aspirin, warfarin, steroids, 
oral retinoid, hormonal or cytotoxic drugs, pregnant 
and lactating females, patients with high andro-
gen levels, irregular menses, acne, or hirsutism, and 
patients presenting with Koebner’s phenomenon, 
thromboembolic manifestations, low serum ferritin, 
and abnormal TSH were excluded from the study.
Informed written consent was obtained from each 
patient, and the study was approved by the Research 
Ethics Committee (REC) at our faculty.
Patients were randomly classified into two equal 
groups via the envelope concealment method as the 
randomization method. Group A (15 patients) ap-
plied topical minoxidil 5% (Scalpovital®) 1 mL in two 
divided doses, once in morning and once at night, 
with proper scalp massaging for 12 weeks; Group B 
(15 patients) was injected intradermally with meso-
therapy (BCN mesoceuticals, Institute BCN – Meso-
therapy Products, Barcelona, Spain). The mesothera-
py mixture contained amino acids (alanine, arginine, 
aspartic acid, cystine, glutamine, glycine, histidine, 
isoleucine, leucine, lysine, phenylalanine, proline, ser-
ine, taurine, and threonine), minerals (zinc, selenium, 
copper, manganese, and chrome), hyaluronic acid 
(1.5%), ginkgo biloba extract, and vitamins (A, C, E, 
and B-complex). 
Injections were performed once weekly during 
12 weeks of treatment. In each session, the volume 
injected was 2 mL, with an average of 40 injection 
points. After disinfection with 70% alcohol, a nappage 
technique was performed by intradermal injections 
of vertex by 0.05 mL solution/site at 1 cm intervals, at 
a depth of 2-4 mm, and at an angle of 30-60 using a 4 
mm long 28 gauge needle (12).
Assessment of treatment response
Our primary outcomes included patient self-as-
sessment and patient satisfaction at the end of the 
12th week; patients were asked to assess the presence 
or absence of improvement in hair density and rate of 
hair loss. Each parameter was assessed as worse, no 
change, and improvement (13). Patient satisfaction 
was evaluated as previously mentioned (10).
Our secondary outcomes included a blinded inves-
tigator’s assessment of the initial treatment response, 
UBM assessment, and any reported side-effects. Clini-
cal improvement was assessed by comparing the pa-
tients’ clinical photos at baseline and 3 months after 
therapy. Initial degree of improvement was assessed 
Table 1. Comparison between the clinical data of both groups




























N: number; SD: Standard deviation.
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according to the grade of change in Ludwig’s classi-
fication as follows: mild and moderate improvement 
if there was improvement that still within the same 
grade (type I, II, or III Ludwig’s classification); good im-
provement if improvement resulted in changing the 
grade to the preceding type; or excellent improve-
ment if improvement resulted in changing the type 
from type III to I or from type I or II to normal (13).
For both groups, UBM assessment was performed 
using the Zeiss Humphrey UBM P45 Plus Mode (Para-
digm Medical Industries, INC) before and 3 months 
after the treatment. The inspection was performed 
using a specially-designed cup (24 mm diameter) that 
produces a water bath environment. This cup is occu-
pied by a viscous, sonolucent connection liquid such 
as methylcellulose (1.0-2.5%). Normal saline was then 
applied to seal this cup. The number of hair follicles 
was determined by calculating the number of non-
echogenic conical shadows reaching the epidermal 
entrance echo (corresponding to the hair follicles). 
Presence of a central keratin plug in some follicles 
was sonographic evidence in addition to the size and 
location (11). The diameter of the largest hair follicle 
detected in this examined area was measured using a 
segmented tool in the UBM screen (10,11). UBM was 
performed by a single experienced investigator, and 
the scans were obtained with the probe oriented per-
pendicular to the examined area in order to obtain a 
clear image and to eliminate bias and artifacts due to 
probe tilt or misalignment. This also ensured repro-
ducibility of the images taken during the follow-up 
visits (in addition to marking the exact location on se-
rial visits, a point 5 cm from the frontal hair line along 
the right side of the sagittal plane). The occurrence of 
any side-effects was accurately described.
Statistical analysis
All statistical calculations were done using SPSS 
(Statistical Package for the Social Science; SPSS Inc., 
Chicago, IL, USA) release 15 for Microsoft Windows 
(2006). Data were described in terms of mean ± stan-
dard deviation (± SD), median and range, or frequen-
cies and percentages when appropriate. Comparison 
of numerical variables was performed using Mann 
Whitney U and Wilcoxon signed rank test. For cate-
gorical data, the Chi square (χ2) test was performed. 
The exact test was used instead when the expected 
frequency was less than 5. Correlations were analysed 
using Pearson moment correlation / Spearman rank 
correlation as appropriate. P values less than 0.05 
were considered statistically significant
RESULTS
Comparison between the clinical data of both 
groups is illustrated in Table 1. There was no statisti-
cally significant difference between both groups re-
garding age, disease duration, and Ludwig classifica-
tion (P=0.177, 0.659, and 0.310, respectively).
Comparison of patient and investigator assess-
ment between groups
No significant difference was found between both 
groups with regard to the initial improvement of the 
hair density and hair loss after treatment (P=0.27 and 
0.056, respectively). Moreover, there was no signifi-
cant difference between groups regarding the degree 
of initial improvement of Ludwig’s classification after 
treatment as assessed by the investigator (P=0.210) 
(Table 2, Figure 1 and Figure 2).
Three months after the treatment, 7 patients 
(23.3%) from group B reported ideal cosmetic results, 
Table 2. Comparison between both groups with regard to initial improvement of hair density and hair 
loss as assessed by the patient, and degree of change in Ludwig’s classification before and after treat-
ment as assessed by the blinded investigator
Clinical Variable Group A (n=15) Group B (n=15) P value
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11 patients (36.7%) (8 patients from group B and 3 
patients from group A) were moderately satisfied, 10 
patients (33.3%) (group A) were slightly satisfied, and 
2 patients (6.7%) (group A) were dissatisfied. A sig-
nificant difference was documented between both 
groups (P=0.001) with the highest degree of satisfac-
tion in the mesotherapy group.
Results of the UBM study in both groups
Group A
The mean number of hair follicles increased after 
treatment, but it did not reach statistical significance 
(P=0.244). Moreover, there was no statistically signifi-
cant difference between the diameter of the largest 
hair follicle before and after treatment (P=0.925) (Ta-
ble 3, Figure 3).
Group B
There was a statistically significant difference be-
tween the number of hair follicles before and after 
treatment (P=0.001). The mean diameter of the larg-
est hair follicle showed some increase after treatment; 
however, it did not reach a statistical significance 
(P=0.105) (Table 3, Figure 3).
Change in the number of hair follicles and 
diameter of the largest hair follicle
A statistically significant difference was found be-
tween groups regarding the increase in the number 
of hair follicle after treatment, with the mesother-
apy group showing more increase (1.166 vs 3.211) 
(P=0.007). There was no significant difference be-
tween the groups regarding the change in the diam-
eter of the largest hair follicle after treatment (0.094 
vs 1.621) (P=0.10) (Figure 4).
Safety and tolerability
In group A, the reported side-effects included hy-
pertrichosis of the face in one case (6.7%), itching in 
66.7% cases (n=10) and scaling in 20% of cases (n=3). 
In group B, the reported side-effects were headache 
in 33.3% of cases (n=5) and pain in 66.7% of cases 
(n=10). Pain at injection sites subsided shortly after 
the session and lasted from several hours to up to 2 
days in some cases. The headache lasted a maximum 
of one day and it did not occur after each session. 
None of our patients reported an allergic reaction to 
the mesotherapy cocktail.
Figure 1. A clinical photo of a female patient before and 
after topical minoxidil showing minimal initial clinical im-
provement.
Figure 2. A clinical photo of a female patient before and af-
ter mesotherapy sessions showing initial clinical improve-
ment.
Table 3. Results of ultrasound biomicroscopy (UBM) study in both groups 
Group A (n=15) P value Group B (n=15) P value
Before treatment After treatment Before treatment After treatment
Hair follicles number 






















N: number; SD: Standard deviation; *P value significant at <0.05
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Figure 4. Comparison between both groups before and 
after treatment. (A) Change in the number of the hair fol-
licles, showing non-significant change in the minoxidil 
group (P=0.244) and a significant increase in the meso-
therapy group (P=0.001); (B) The diameter of the largest fol-
licle, showing no change in the minoxidil group (P=0.925) 
and a non-significant change in the mesotherapy group 
(P=0.105).
(14-18). What differentiates our study from the previ-
ous works is the use of an objective tool, ultrasound 
biomicroscopy, in the evaluation of hair regrowth 
after treatment. Most of the previous studies relied 
on the patient’s and investigator’s assessment of the 
condition, in addition to villous hair count in some 
studies (15).
The ultrasonographic results of group B (meso-
therapy group) revealed a significant initial clinical 
improvement by showing an increased number of 
hair follicles after treatment. However, no significant 
improvement was found in the diameter of the larg-
est hair follicles after treatment. This lack of signifi-
cant improvement could be explained by the short 
treatment duration and the assessment of a single 
hair diameter. These ultrasonographic findings were 
matched the results of both the patient’s self-assess-
ment and the investigator’s judgment.
To the best of our knowledge, there were no pre-
vious reports in the literature on the effect of me-
sotherapy injections on FPHL, including the use of 
nutritional supplements only. Moftah et al. (19) evalu-
ated the efficacy and safety of mesotherapy using 
DISCUSSION
In the present pilot study, the initial efficacy of 
both therapeutic modalities, topical minoxidil 5% 
and mesotherapy for the treatment of FPHL, was con-
firmed both subjectively and objectively. 
Although the results of UBM assessment in the 
minoxidil group revealed no significant initial clinical 
improvement, there was an improvement in Ludwig’s 
classification and some of the patients reported ini-
tial improvement in their hair density and rate of hair 
loss. UBM can provide an objective assessment of the 
clinical improvement. UBM pictures the hair follicles 
at the reticular dermis and enables earlier detection 
of re-growing hair follicles (10). The lack of significant 
ultrasonographic results in the current study may 
be related to the low number of patients involved 
or to the duration of treatment, which was 12 weeks 
long, due to being limited by the cost of medications; 
moreover, it would have been better to measure the 
median or mean of diameters of a greater number of 
hair follicles rather than just one.  
There are several studies in literature on the ef-
ficacy of topical minoxidil in the treatment of FPHL 
Figure 3. Ultrasound biomicroscopy (UBM) images in both 
groups before (top images) and after (bottom images), hair 
follicles are outlined in red. Red circles refer to the site of the 
hair follicles for measurement of their number and diam-
eter. (A) A female patient in the topical minoxidil group; (B) 
A female patient in the mesotherapy group.
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a dutasteride preparation in the treatment of FPHL. 
However, they used commercial preparation, which 
contained dutasteride together with other vitamins, 
because it was the only preparation available in the 
Egyptian market that contained dutasteride at the 
time of study commencement. They attributed im-
provement in hair quality as assessed by the patient 
to biotin, pyridoxine, and pantothenic acid present in 
the formulation used, as they are known to improve 
hair color, texture, and thickness as previously report-
ed by Boccaletti et al. (20).
There were no statistically significant findings 
when comparing the groups (topical minoxidil 5% 
vs mesotherapy) regarding initial clinical improve-
ment, change of the number of hair follicles, and the 
diameter of the largest hair follicle before and after 
treatment, apart from the increase in the number of 
hair follicles after treatment, which was better in the 
mesotherapy group.
In both groups, we observed a discrepancy be-
tween patient self-assessment in those who were 
not completely satisfied and the improvement of 
their condition as judged by the investigator who ob-
served initial improvement as monitored by the de-
gree of change in Ludwig’s classification. This might 
be related to the impact of the disease on the psy-
chological and social activities of patients, thereby 
reducing their quality of life (QoL) (1). Patients were 
more satisfied with the mesotherapy modality, which 
might reflect the preferred psychological role of me-
sotherapy in many patients irrespective of the agent 
used (21). 
The side-effects in the mesotherapy group in this 
study were minimal and tolerable, a finding which 
was consistent with previous studies (19,22). How-
ever, serious side-effects such as multifocal scalp 
abscess with subcutaneous fat necrosis and scarring 
alopecia as complications of scalp mesotherapy (23) 
were not detected in the current study.
The limitations of the current study included the 
low number of cases, relatively short duration of treat-
ment due to the cost of the medications, lack of an-
other objective tool “such as dermoscopy/folliscope/
histopathology” to validate the method of counting 
hair numbers and measuring hair diameter, and the 
inability of the available UBM machine to precisely 
locate the superficial venous plexus which could 
have facilitated the calculation of hair follicles in each 
phase (anagen/telogen). Future studies considering 
these limitations are strongly recommended.
CONCLUSION 
Mesotherapy with vitamins and minerals only is 
an effective, more acceptable to patients, and more 
tolerable modality compared with topical minoxidil 
5% in the treatment of FPHL.
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